Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Keytruda
Pharma
Increased deaths shadow Enhertu’s first-line lung cancer data
Enhertu showed a preliminary 15% increased risk of death compared to Keytruda plus chemo in the Destiny-Lung04 study in first-line HER2-mutant NSCLC.
Angus Liu
Sep 13, 2026 7:00pm
Ivonescimab tops Keytruda with strong OS in PD-L1-high NSCLC
Sep 13, 2026 8:00am
Failed Trodelvy first-line NSCLC trial shows better China data
Sep 12, 2026 9:45pm
Merck to lay off another 54 at New Jersey HQ
Sep 9, 2026 11:10am
Akeso, Summit’s ivonescimab hits OS goal in Keytruda head-to-head
Sep 3, 2026 10:29am
Merck touts Keytruda front-line win in endometrial cancer subtype
Jul 15, 2026 3:33pm
